02-Nov-2026 08:28:07
SUNPHARMAGeneral news
HSBC ON SUN PHARMA ; BUY | TP ₹2,050 (EARLIER ₹2,100)
• Global innovative medicine sales UP 6.9% YoY at $356 Mn, impacted by slower US Ilumya sales. • US FDA approves Ilumya for psoriatic arthritis, expanding its addressable market. • Ilumya launch for psoriatic arthritis planned from November. • Cuts FY27–29 EPS estimates by 2.5–3.1%. • Ilumya recovery and European lerodalcibep launch remain key growth catalysts.
SUN PHARMACEUTICAL IND L